The Pfizer COVID-19 vaccine has a strong safety record backed by clinical trials, real-world surveillance of hundreds of millions of doses, and full FDA approval. Most people experience only mild, short-lived side effects like arm soreness and fatigue. Serious adverse events, including heart inflammation, occur but are rare and concentrated in specific age and sex groups.
Common Side Effects and How Long They Last
The most frequent reaction is pain at the injection site, reported by roughly 78–83% of adults aged 18 to 55 after either dose. Fatigue is the next most common, affecting about 47% after the first dose and 59% after the second. Headache follows a similar pattern: 42% after dose one, rising to 52% after dose two. Fever is much less common, occurring in about 4% after the first dose and 16% after the second.
Side effects tend to be milder in older adults. Among people over 55, injection site pain drops to about 66–71%, fatigue to 34–51%, and headache to 25–39%. Fever after the second dose hits about 11%, compared to 16% in younger adults. Children aged 5 to 11 also report lower rates of fatigue and headache than teenagers, and fever stays under 7%.
These reactions typically start within a day or two of the shot and clear up within 48 to 72 hours. They’re signs that your immune system is responding to the vaccine. The second dose tends to produce stronger reactions than the first, which is normal for vaccines that use a prime-boost schedule.
Heart Inflammation: Who’s at Risk
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) are the most discussed serious side effects. The risk is real but small, and it’s concentrated in one demographic: adolescent and young adult males after the second dose.
CDC data from 40 U.S. health systems found that within seven days of the second dose, myocarditis occurred in about 22 per 100,000 males aged 12 to 17, and about 6.5 per 100,000 males aged 18 to 29. For females in those same age groups, the rates were roughly 1.1 and 1.6 per 100,000, respectively. Among males and females over 30, rates dropped below 1 per 100,000 after the second dose. No cases were detected in children aged 5 to 11 of either sex.
When vaccine-related myocarditis does occur, it tends to be mild. The median hospital stay is about one day, compared to six days for a COVID-19 hospitalization. Most cases resolve with rest and anti-inflammatory treatment. Spacing the first and second doses eight weeks apart, rather than the original three-week interval, may further reduce this already small risk, according to current CDC guidance.
Severe Allergic Reactions
Anaphylaxis, a severe allergic reaction, was reported at a rate of about 11 cases per million first doses during the initial U.S. rollout. That’s roughly 1 in 90,000. Nearly all cases occurred within 30 minutes of vaccination, which is why you’re asked to wait at the vaccination site for 15 to 30 minutes afterward. Most people who experienced anaphylaxis had a history of allergic reactions, and all confirmed cases were treatable with standard emergency protocols.
Safety in Children
In the clinical trial that led to authorization for children aged 5 to 11, Pfizer vaccinated over 3,100 kids. Local reactions like arm soreness were reported by about 86%, and systemic reactions like fatigue or headache by about 67%. Most were mild, meaning they didn’t interfere with normal daily activities. No serious adverse events related to the vaccine were identified in the trial.
Post-authorization monitoring confirmed a similar picture. Young children reported fewer and milder side effects than teenagers. Fever stayed under 7% after the second dose in the 5-to-11 group, compared to nearly 20% in 12-to-15-year-olds. Myocarditis was not detected in the 5-to-11 age group in the large CDC dataset covering the first year of use.
Safety During Pregnancy
A large study published in JAMA found that infants born to vaccinated mothers had no increased risk of adverse outcomes. In fact, vaccinated pregnancies showed lower rates of certain complications: neonatal brain hemorrhage occurred at 1.7 per 1,000 births in the vaccinated group versus 3.2 in the unvaccinated group, and neonatal mortality was 0.9 versus 1.8 per 1,000. Previous research has consistently found no increased risk of miscarriage, stillbirth, or preterm birth associated with COVID-19 vaccination during pregnancy.
How the Vaccine Works in Your Body
The Pfizer vaccine delivers a small piece of genetic instructions (mRNA) that teaches your cells to produce a harmless fragment of the virus’s spike protein. Your immune system recognizes this protein as foreign, mounts a response, and builds memory cells that can fight the actual virus later. The mRNA itself breaks down within a few days, and the spike proteins your cells produce are cleared within a few weeks, just like any other protein your body makes and recycles. Nothing from the vaccine integrates into your DNA.
Benefits Compared to Risks
The FDA modeled the benefit-risk balance for every age group before granting authorization. Under most scenarios, including periods of moderate COVID-19 transmission, the number of hospitalizations, ICU admissions, and deaths prevented by vaccination clearly outweighed the number of myocarditis cases caused. The only scenario where the math got closer was during the lowest period of COVID-19 transmission among males, and even then the FDA noted that COVID hospitalizations are more severe (averaging six days) than myocarditis hospitalizations (averaging one day), tipping the overall balance in favor of vaccination.
For adults over 30 and for females of all ages, the benefit-risk calculation is overwhelmingly favorable because myocarditis rates in those groups are extremely low. For adolescent and young adult males, the benefits still outweigh the risks under most real-world conditions, particularly when an extended eight-week dosing interval is used.
Current FDA Approval Status
The Pfizer vaccine, marketed under the brand name Comirnaty, holds full FDA approval rather than just emergency use authorization. As of August 2025, the FDA approved the updated 2025–2026 formula for individuals 12 and older who are 65 or older or have at least one underlying condition that puts them at high risk for severe COVID-19, as well as a lower-dose version for high-risk children aged 5 to 11. This full approval reflects the FDA’s conclusion, based on years of data from clinical trials and real-world use, that the vaccine meets the agency’s standard for safety and effectiveness.